Hester Biosciences (BOM:524669) EBIT: ₹868 Mil (TTM As of Mar. 2026)


BOM:524669 Hester Biosciences Ltd BOM:524669
73 GF Score
Price ₹2,193.45
GF Value ₹1,885.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Hester Biosciences EBIT?

Hester Biosciences BOM:524669 +1.48% 73 EBIT is ₹868 Mil as of Mar. 2026. GuruFocus rates BOM:524669 with a GF Score™ of 73/100 and a GF Value™ of ₹1,885.73 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Hester Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹302 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹868 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hester Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 was 11.83%. Hester Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hester Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.20%.

Hester Biosciences  (BOM:524669) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hester Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1136.72 * ( 1 - 34.05% )/( (0 + 6334.51)/ 1 )
=749.66684/6334.51
=11.83 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6779.41 - 415.49 - ( 29.41 - max(0, 1524.78 - 2085.62+29.41))
=6334.51

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Hester Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1207.32/( ( (0 + max(0, 0)) + (4135.94 + max(1458.2, 0)) )/ 1 )
=1207.32/( ( 0 + 5594.14 )/ 1 )
=1207.32/5594.14
=21.58 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(953.56 + 725.33 + 318.9) - (415.49 + 0 + 124.1)
=1458.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hester Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=867.69/20653.453
=4.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hester Biosciences EBIT Related Terms

Hester Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Hester Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hester Biosciences EBIT Chart

Hester Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 560.78 453.03 410.72 479.11 832.52

Hester Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.65 219.97 192.43 153.46 301.83

BOM:524669 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hester Biosciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hester Biosciences's EV-to-EBIT falls into.


BOM:524669
73GF Score
Hester Biosciences Ltd BOM:524669
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hester Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹868 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹868 Mil mean?
Hester Biosciences (BOM:524669) has a EBIT of ₹868 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hester Biosciences.
Is Hester Biosciences' EBIT too high?
Hester Biosciences' current EBIT is ₹868 Mil. Overall, Hester Biosciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' EBIT compare to ZTS and UTHR?
Hester Biosciences' EBIT of ₹868 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hester Biosciences. Hester Biosciences's current EBIT is ₹868 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,885.73, compared to a current price of ₹2,193.45 — trading 16.3% above its estimated fair value. The current EBIT is ₹868 Mil. Hester Biosciences' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current EBIT is ₹868 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hester Biosciences (BOM:524669) Overvalued in 2026?

Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued. The current stock price of ₹2,193.45 is trading 16.3% above its estimated GF Value™ of ₹1,885.73. GuruFocus considers Hester Biosciences to be Modestly Overvalued.

Key valuation signals for BOM:524669:

  • EBIT: ₹868 Mil
  • GF Value™: ₹1,885.73 vs. price of ₹2,193.45 (16.3% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hester Biosciences Business Description

Other Exchanges HESTERBIO:India
Address Village Meda - Adraj, Taluka Kadi, District Mehsana, Mehsana, GJ, IND, 384441
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
73GF Score

Get the complete analysis for BOM:524669

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,193.45
Price
₹1,885.73
GF Value